The Specific Aim of the Molecular Diagnostics Core is to support Projects by performing assays integral to the completion of their Specific Aims. Specifically, for Project 2 we will perform FLT3-ITD allelic ratio to define eligibility for Protocol #2487, as well as testing for FLT3-ITD allelic ratio. FLT3 and cKIT mutation studies in paired diagnostic and relapse samples, per protocol requirements. For the CAL101 trial, we will use IgH VDJ rearrangements to monitor disease burden as a measure of response. For Project 3. we will perform WTl expression studies for protocol #2498. on samples taken before, during, and at relapse, using flow cytometry to isolate AML blasts (via Core A). In addition, select samples will have single cell analyses performed to note the heterogeneity of WTl expression. Lastly, for protocol #2495 in Project 4, we will perform IgH VDJ and RORI expression to monitor disease burden and response, and perform gene expression analyses on pre- and relapsed samples to investigate pathways associated with resistance. These assays are integral to the aims of these protocols, and the assays are not available in commercial laboratories. The Radich Lab is a CAP/CLIA certified laboratory involved in studying the molecular genetics of leukemia and devising clinically useful tests more molecular diagnostics and monitoring. The lab has serviced as the North American molecular core for -10 CML industry trials, as well as the core of SWOG trials in ALL, CML, and AML, and as the central molecular core for the last and current COG AML trial, as well as establishing collaborations with biotechnology to develop new platforms for molecular diagnostics Cepheid, Fluidigm, and Nanostring.

Public Health Relevance

Molecular diagnostics are an important tool in understanding the biology of response, as well as providing an important and powerful tool in disease monitoring. The activities of Core B will help investigators more accurately measure the effectiveness of their therapeutic interventions, as well as help understand which patients become resistant to therapy, and why.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-T)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Jagasia, Madan H; Greinix, Hildegard T; Arora, Mukta et al. (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21:389-401.e1
Walter, R B; Gyurkocza, B; Storer, B E et al. (2015) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29:137-44
Walter, Roland B; Sandmaier, Brenda M; Storer, Barry E et al. (2015) Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transplant 21:373-8
Mielcarek, Marco; Kirkorian, Anna Yasmine; Hackman, Robert C et al. (2014) Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation. Transplantation 98:563-8
Hoffmeister, Paul A; Storer, Barry E; Baker, K Scott et al. (2014) Nephrolithiasis in pediatric hematopoietic cell transplantation with up to 40 years of follow-up. Pediatr Blood Cancer 61:417-23
Stromnes, Ingunn M; Schmitt, Thomas M; Chapuis, Aude G et al. (2014) Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 257:145-64
Boyle, Nicole M; Podczervinski, Sara; Jordan, Kim et al. (2014) Bacterial foodborne infections after hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:1856-61
Li, Xiang; Deeg, H Joachim (2014) Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. Exp Hematol 42:4-10
Fisher, C E; Stevens, A M; Leisenring, W et al. (2014) Independent contribution of bronchoalveolar lavage and serum galactomannan in the diagnosis of invasive pulmonary aspergillosis. Transpl Infect Dis 16:505-10
Raj, Kavita; Pagliuca, Antonio; Bradstock, Kenneth et al. (2014) Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 20:890-5

Showing the most recent 10 out of 1666 publications